Cholecystokinin Evokes Secretion of Oxytocin and Vasopressin from Rat

Total Page:16

File Type:pdf, Size:1020Kb

Cholecystokinin Evokes Secretion of Oxytocin and Vasopressin from Rat Proc. Natl. Acad. Sci. USA Vol. 86, pp. 5198-5201, July 1989 Neurobiology Cholecystokinin evokes secretion of oxytocin and vasopressin from rat neural lobe independent of external calcium (neurohypophysis/receptors/neurosecretion/neuropeptide/protein kinase C) C. A. BONDY*t, R. T. JENSEN*, L. S. BRADY§, AND H. GAINER* *Laboratory of Neurochemistry, National Institute of Neurological and Communicative Disorders and Stroke, tDigestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, and §Unit on Functional Neuroanatomy, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 Communicated by William A. Hagins, April 5, 1989 ABSTRACT Cholecystokinin (CCK) and its receptors are albumin (1.5 mg/ml)] maintained at 370C and equilibrated abundantly represented in the central nervous system. However, with frequent washes for 90 min prior to starting the exper- a specific role or mechanism ofaction for CCKin this context has iment. The incubation and stimulus assembly have been not been established. CCK coexists with oxytocin in magnocel- described in detail elsewhere (4). The stream of 02 suffusing lular neurons of the hypothalamic-neurohypophysial system, the medium was turned offduring periods of peptide addition sharing common neurosecretory vesicles with oxytocin in the (and for the same period in control preparations) to avoid neural lobe of the pituitary. The neural lobe, which consists oxidation of CCK and related peptides, which can destroy primarily of oxytocin- and vasopressin-containing axons and their activity. Medium was collected at 5- or 10-min intervals nerve terminals and their surrounding glia, provides a relatively for determination of OT and VP content by specific radio- simple model system allowing for the study of the regulation of immunoassay as described (4). Peptides werf obtained from neurosecretion at the nerve terminal level, free from the complex Peninsula Laboratories, the CCK antagonist L-364,718 was array of synaptic effects present throughout the rest of the from Merck Sharp & Dohme, and staurosporine was from central nervous system. In this paper, we demonstrate the Kyowa Medex (Tokyo). presence ofhigh-affinity CCK binding sites in the rat neural lobe For CCK receptor studies, pituitaries were dissected from and show that activation of these receptors by the sulfated male Sprague-Dawley rats, rinsed in room temperature nor- octapeptide, CCK-8, and related peptides causes potent secre- mal saline, and frozen directly in Lab-Tek O.C.T. compound tion of oxytocin and vasopressin from the isolated nerve termi- embedding matrix over dry ice. They were cut into 12- nals. The secretagogue action of CCK-8, which is blocked by a ,m-thick sections at -15'C and thaw mounted onto gelati- CCK receptor antagonist (L-364,718), is independent of electri- nized slides. After drying, they were preincubated in 50 mM cal stimulation and extracellular calcium and is blocked by an Tris-HCl (pH 7.4) containing 0.5% bovine serum albumin for inhibitor of protein kinase C. Thus, the action of CCK on the 20 min at 240C, then incubated in 10 mM Hepes (pH 6.5) neural lobe provides an example of peptide ligand-induced containing 0.5% bovine serum albumin, 0.025% bacitracin, neurosecretion apparently mediated by second messengers leupeptin (4 gg/ml), 130 mM NaCl, 4.5 mM KCI, 5 mM rather than depolarization-induced calcium influx. MgCl2, 1 mM EGTA, and 0.125 nM 1251I-labeled CCK-8 (Amersham) for 2 hr at 240C. After the incubation, slides Since cholecystokinin (CCK) is colocalized in neurosecre- underwent six 15-min washes in 5% bovine serum albumin at tory granules with oxytocin (OT) in the hypothalamic- 40C and were dried and apposed to LKB Ultrofilm for 12 neurohypophysial system (18), it would be expected that days. these two peptides are co-released from the nerve terminals of the neural lobe (NL). Supporting this view are the obser- vations that CCK immunoreactivity is lost as a result of stalk RESULTS section, and physiologic stimuli that result in depletion ofOT To test the effect of CCK on electrically evoked secretion also cause a marked depletion of NL CCK (1). The molar from the NL, we used a low-frequency, low-intensity elec- concentration of CCK in the rat NL is several orders of trical stimulus protocol that elicits relatively low but reliable magnitude less than that of OT (1), suggesting that the CCK levels of OT and VP secretion. This protocol was chosen to secreted with OT plays a local rather than systemic role. minimize the release of endogenous copeptides, so as not to Since other colocalized peptides-namely, dynorphin (2) and obscure their effects when added experimentally (2). It was corticotropin-releasing factor (3)-have been found to play a found that CCK-8 (0.1 nM) did not affect the electrically role in the regulation of neurohypophysial hormone secre- evoked release of OT (Fig. 1A) or VP (unpublished data) but tion, we investigated the effects of CCK on the release of OT instead caused an episode of secretion that proved to be and vasopressin (VP) from isolated rat NLs. completely independent of electrical stimulation (Fig. 1B). Furthermore, unlike the immediate response to electrically MATERIALS AND METHODS stimulated secretion, CCK-evoked secretion was delayed, reaching a peak 40-50 min after first exposure to the peptide Pituitaries were removed from male Sprague-Dawley rats (Fig. 1). (200-250 g) and NLs were freed from intermediate lobe tissue No prior episode of electrical stimulation (i.e., S1) was under a dissecting microscope. NLs were singly impaled on in stimulating electrodes immersed in oxygenated physiologic necessary for the action ofCCK, as was found experiments saline [140 mM NaCl/4.5 mM KCl/1.5 mM MgCl2/2.0 mM in which electrical stimulation was omitted altogether (un- CaCl2/10 mM Hepes, pH 7.3/10 mM dextrose/bovine serum Abbreviations: CCK, cholecystokinin; CCK-8, cholecystokinin sul- fated octapeptide; NL, neural lobe; OT, oxytocin; VP, vasopressin; The publication costs of this article were defrayed in part by page charge PKC, protein kinase C. payment. This article must therefore be hereby marked "advertisement" tTo whom reprint requests should be addressed at: Building 36, in accordance with 18 U.S.C. §1734 solely to indicate this fact. Room 4D20, National Institutes of Health, Bethesda, MD 20892. 5198 Downloaded by guest on September 25, 2021 Neurobiology: Bondy et al. Proc. Natl. Acad. Sci. USA 86 (1989) 5199 A 0 OCK * CONTROL ba 0 C/) 2 80 Minutes o 10o12 10-11 1010 10-9 10-8 10o7 B 2.5 - CCK-8 logM FIG. 2. Dose-response relationship for stimulation by CCK-8 of 2.0 - VP and OT release from isolated rat NLs. Experiments were performed as shown in Fig. 1B. Data are expressed as S2/S1 ratios, 1.5 - which were determined for each individual preparation as follows: 04 hormone released over 30 min following the standard electrical to stimulus (subtracting basal release determined in the period imme- 1.0 - diately preceding the stimulus) = S1; hormone released during the 110 min following exposure to test substances (subtracting basal level 0.5 n of hormone secretion demonstrated in the period prior to exposure) = S2. Each point represents the mean ± SEM of five to seven n% 1 _ experiments at each concentration. The zero point represents S2/S1 40 80 120 160 200 values for controls (no peptide exposure during the S2 period). r_ Minutes exposure to CCK or related peptides, as explained in the 0 C calcium-free legend to Fig. 2. 1.5 - Electrically evoked secretion from the nerve terminals of * the NL is dependent on depolarization-induced calcium influx (5) and does not occur when calcium is absent from the external medium, as shown in Fig. 1C, where release to the 1.0- second period of electrical stimulation, indicated by the arrow, is abolished. CCK-8, however, evoked OT and VP 04 secretion in calcium-free medium, as shown in Fig. 1C and 0.5- also in Table 1 (in the latter experiments, there was no second electrical stimulation). CCK also produced secretion in me- Table 1. Effects of CCK-8 and related peptides on VP and OT secretion from isolated rat neural lobes 40 80 1 20 Minutes S2/S1 Treatment OT VP FIG. 1. CCK-8 stimulates secretion from isolated NLs indepen- ± ± dently of electrical stimulation. (A) Effects of CCK-8 (0.1 nM) on CCK-8 (1 nM) 6.689 1.032 4.157 0.636 electrically evoked secretion of OT using a low-frequency double CCK-8 (1 nM), calcium-free 6.054 ± 0.641 4.202 ± 0.545 electrical stimulus (ES) protocol. In these experiments, each NL CCK-8 (1 nM) + staurosporine 0.777 ± 0.246* 0.935 ± 0.344* received two identical periods of ES (arrows), consisting of 1000 CCK-8 (1 nM) + L-364,718 5.874 ± 0.854 3.567 ± 0.873 pulses of 3 V and 0.5 ms at 6 Hz. Controls (o; n = 3) underwent both CCK-8 (0.1 nM) 3.330 ± 0.532 2.549 ± 0.226 stimuli in control medium, while experimental animals (o; n = 3) CCK-8 (0.1 nM), nonsulfated 2.810 ± 0.700 3.432 ± 0.817 were exposed to CCK during the second stimulus period, as shown CCK-4 (0.1 nM) 0.278 ± 0.094* 0.493 ± 0.233t by the solid bar along the abscissa. (B) Experiments (n = 6) in which Gastrin I (0.1 nM) (human) 2.535 ± 0.297 3.162 ± 0.969 the second ES was omitted and the effect ofCCK (0.1 nM) on resting CCK-8 (0.1 nM) + L-364,718 0.332 ± 0.067* 0.159 ± 0.091* secretion is shown.
Recommended publications
  • Oxytocin Is an Anabolic Bone Hormone
    Oxytocin is an anabolic bone hormone Roberto Tammaa,1, Graziana Colaiannia,1, Ling-ling Zhub, Adriana DiBenedettoa, Giovanni Grecoa, Gabriella Montemurroa, Nicola Patanoa, Maurizio Strippolia, Rosaria Vergaria, Lucia Mancinia, Silvia Coluccia, Maria Granoa, Roberta Faccioa, Xuan Liub, Jianhua Lib, Sabah Usmanib, Marilyn Bacharc, Itai Babc, Katsuhiko Nishimorid, Larry J. Younge, Christoph Buettnerb, Jameel Iqbalb, Li Sunb, Mone Zaidib,2, and Alberta Zallonea,2 aDepartment of Human Anatomy and Histology, University of Bari, 70124 Bari, Italy; bThe Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029; cBone Laboratory, The Hebrew University of Jerusalem, Jerusalem 91120, Israel; dGraduate School of Agricultural Science, Tohoku University, Aoba-ku, Sendai, Miyagi 981-8555 Japan; and eCenter for Behavioral Neuroscience, Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30322 Communicated by Maria Iandolo New, Mount Sinai School of Medicine, New York, NY, February 19, 2009 (received for review October 24, 2008) We report that oxytocin (OT), a primitive neurohypophyseal hor- null mice (5). But the mice are not rendered diabetic, and serum mone, hitherto thought solely to modulate lactation and social glucose homeostasis remains unaltered (9). Thus, whereas the bonding, is a direct regulator of bone mass. Deletion of OT or the effects of OT on lactation and parturition are hormonal, actions OT receptor (Oxtr) in male or female mice causes osteoporosis that mediate appetite and social bonding are exerted centrally. resulting from reduced bone formation. Consistent with low bone The precise neural networks underlying OT’s central effects formation, OT stimulates the differentiation of osteoblasts to a remain unclear; nonetheless, one component of this network mineralizing phenotype by causing the up-regulation of BMP-2, might be the interactions between leptin- and OT-ergic neurones which in turn controls Schnurri-2 and 3, Osterix, and ATF-4 expres- in the hypothalamus (10).
    [Show full text]
  • Reorganization of Neural Peptidergic Eminence After Hypophysectomy
    The Journal of Neuroscience, October 1994, 14(10): 59966012 Reorganization of Neural Peptidergic Systems Median Eminence after Hypophysectomy Marcel0 J. Villar, Bjiirn Meister, and Tomas Hiikfelt Department of Neuroscience, The Berzelius Laboratory, Karolinska Institutet, Stockholm, 171 77 Sweden Earlier studies have shown the formation of a novel neural crease to a final stage of a few, strongly immunoreactive lobe after hypophysectomy, an experimental manipulation fibers in the external layer at longer survival times. Vaso- that causes transection of neurohypophyseal nerve fibers active intestinal polypeptide (VIP)- and peptide histidine- and removal of pituitary hormones. The mechanisms that isoleucine (PHI)-IR fibers in hypophysectomized animals had underly this regenerative process are poorly understood. already contacted portal vessels 5 d after hypophysectomy, The localization and number of peptide-immunoreactive and from then on progressively increased in numbers. Fi- (-IR) fibers in the median eminence were studied in normal nally, most of the peptide fibers described above formed rats and in rats at different times of survival after hypophy- dense innervation patterns around the large blood vessels sectomy using indirect immunofluorescence histochemistry. along the lateral borders of the median eminence. The number of vasopressin (VP)-IR fibers increased in the The present results show that hypophysectomy induces external layer of the median eminence in 5 d hypophysec- a wide variety of changes in hypothalamic neurosecretory tomized rats. Oxytocin (OXY)-IR fibers decreased in the in- fibers. Not only is the expression of several peptides in these ternal layer and progressively extended into the external fibers modified following different survival times, but a re- layer.
    [Show full text]
  • Oxytocin Effects in Mothers and Infants During Breastfeeding
    © 2013 SNL All rights reserved REVIEW Oxytocin effects in mothers and infants during breastfeeding Oxytocin integrates the function of several body systems and exerts many effects in mothers and infants during breastfeeding. This article explains the pathways of oxytocin release and reviews how oxytocin can affect behaviour due to its parallel release into the blood circulation and the brain. Oxytocin levels are higher in the infant than in the mother and these levels are affected by mode of birth. The importance of skin-to-skin contact and its association with breastfeeding and mother-infant bonding is discussed. Kerstin Uvnäs Moberg Oxytocin – a system activator increased function of inhibitory alpha-2 3 MD, PhD xytocin, a small peptide of just nine adrenoceptors . Professor of Physiology amino acids, is normally associated The regulation of the release of oxytocin Swedish University of Agriculture O with labour and the milk ejection reflex. is complex and can be affected by different [email protected] However, oxytocin is not only a hormone types of sensory inputs, by hormones such Danielle K. Prime but also a neurotransmitter and a as oestrogen and even by the oxytocin 1,2 molecule itself. This article will focus on PhD paracrine substance in the brain . During Breastfeeding Research Associate breastfeeding it is released into the brain of four major sensory input nervous Medela AG, Baar, Switzerland both mother and infant where it induces a pathways (FIGURES 2 and 3) activated by: great variety of functional responses. 1. Sucking of the mother’s nipple, in which Through three different release pathways the sensory nerves originate in the (FIGURE 1), oxytocin functions rather like a breast.
    [Show full text]
  • Physiology of Hypothalamus and Pituitary
    Physiology of Hypothalamus and Pituitary Simge Aykan, PhD Department of Physiology Ankara University School of Medicine Pituitary Gland • Pituitary gland (hypophysis) is two different tissue types that merged during embryonic development • Anterior pituitary (adenohypophysis): true endocrine gland of epithelial origin • Posterior pituitary (neurohypophysis): extension of the neural tissue of the brain • secretes neurohormones made in the hypothalamus Pituitary Gland • Pituitary bridges and integrates the neural and endocrine mechanisms of homeostasis. • Highly vascular • Posterior pituitary receives arterial blood • anterior pituitary receives only portal venous inflow from the median eminence. • Portal system is particularly important in its function of carrying neuropeptides from the hypothalamus and pituitary stalk to the anterior pituitary. Posterior Pituitary • Storage and release site for two neurohormones (peptide hormones) • Oxytocin • Vasopressin (antidiuretic hormone; ADH) • Large diameter neurons producing hormones are clustered in hypothalamus at paraventricular (oxytocin) and supraoptic nuclei (ADH) • Secretory vesicles containing neurohormones transported to posterior pituitary through axons of the neurons • Stored at the axons until a release signal arrives • Depolarization of the axon terminal opens voltage gated Ca2+ channels and exocytosis is triggered • Hormones release to the circulation Posterior Pituitary • The posterior pituitary regulates water balance and uterine contraction • Vasopressin (ADH), is a neuropeptide
    [Show full text]
  • Effect of Early Vasopressin Vs Norepinephrine On
    Protocol Number: CRO1888 VANISH Vasopressin vs Noradrenaline as Initial therapy in Septic Shock PROTOCOL NUMBER: CRO1888 EudraCT NUMBER: 2011-005363-24 SPONSOR: Imperial College London FUNDER: National Institute for Health Research DEVELOPMENT PHASE: PHASE IV STUDY COORDINATION CENTRE: Imperial Clinical Trials Unit PROTOCOL Version & Date: Version 2.1, 02.08.2013 Property of: Dr Anthony Gordon May not be used, divulged or published without the consent of: Dr Anthony Gordon Confidential Final Version2.1, 02.08.2013 Page 1 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 Study Management Group Chief Investigator: Dr Anthony Gordon Co-investigators: Dr Stephen Brett Prof Gavin Perkins Prof Deborah Ashby Statistician: Dr Alexina Mason Trial Management: Ms Neeraja Thirunavukkarasu Study Coordination Centre For general queries, supply of trial documentation, and collection of data, please contact: Study Coordinator: Ms Neeraja Thirunavukkarasu Address: ICU – 11N, Charing Cross Hospital, Fulham Palace Road London W6 8RF E-mail: [email protected] Clinical Queries Clinical queries should be directed to Ms Neeraja Thirunavukkarasu who will direct the query to the appropriate person Sponsor Imperial College London is the main research Sponsor for this study. For further information regarding the sponsorship conditions, please contact the Head of Regulatory Compliance at: Joint Research Compliance Office 510, Lab block, 5th Floor Charing Cross Hospital Fulham Palace Road London W6 8RF Tel: 0203 311 0213 Fax: 0203 311 0203 Funder National Institute for Health Research – Research for Patient Benefit and Clinician Scientist award schemes This protocol describes the VANISH study and provides information about procedures for entering participants.
    [Show full text]
  • Vasopressin Versus Norepinephrine in Septic Shock: a Propensity Score Matched Efficiency Retrospective Cohort Study in the VASST Coordinating Center Hospital James A
    Russell et al. Journal of Intensive Care (2018) 6:73 https://doi.org/10.1186/s40560-018-0344-2 RESEARCH Open Access Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital James A. Russell1,2*, Hugh Wellman3 and Keith R. Walley1,2 Abstract Purpose: It is not clear whether vasopressin versus norepinephrine changed mortality in clinical practice in the Vasopressin and Septic Shock Trial (VASST) coordinating center hospital after VASST was published. We tested the hypothesis that vasopressin changed mortality compared to norepinephrine using propensity matching of vasopressin to norepinephrine-treated patients in the VASST coordinating center hospital before (SPH1) and after (SPH2) VASST was published. Methods: Vasopressin-treated patients were propensity score matched to norepinephrine-treated patients based on age, APACHE II, respiratory, renal, and hematologic dysfunction, mechanical ventilation status, medical/surgical status, infection site, and norepinephrine dose. The propensity score estimated the probability that a patient would have received vasopressin given baseline characteristics. For sensitivity analysis, we then excluded patients who had underlying severe congestive heart failure. The primary outcome was 28-day mortality. Results: Vasopressin- and norepinephrine-treated patients were similar after matching in SPH1 (pre-VASST); vasopressin-treated patients (n = 158) had a significantly higher mortality than norepinephrine-treated patients (n = 158) (60.8 vs. 46.2%, p = 0.009). In SPH2 after matching, the 28-day mortality rates were not significantly different; 31.2% and 26.9% in the vasopressin (n = 93) and norepinephrine (n = 93) groups, respectively (p = 0.518). The day 1 vasopressin dose in SPH1 vs.
    [Show full text]
  • Transition from Biological to Chemical Assay for Quality Assurance of Medicinal Substances (Apis) and Formulated Preparations
    WHO/BS/07.2070 ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva - 8 to 12 October 2007 Discussion paper: Transition from biological to chemical assay for quality assurance of medicinal substances (APIs) and formulated preparations A Bristow National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK ML Rabouhans, J Joung, DJ Wood World Health Organization, Geneva, Switzerland © World Health Organization 2007 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected] ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Oxytocin to Accelerate Or Induce Labour
    CLINICAL PRACTICE GUIDELINE OXYTOCIN CLINICAL PRACTICE GUIDELINE OXYTOCIN TO ACCELERATE OR INDUCE LABOUR Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and the Clinical Strategy and Programmes Division, Health Service Executive Version: 1.0 Publication date: April 2016 Guideline No: 36 Revision date: April 2019 CLINICAL PRACTICE GUIDELINE OXYTOCIN Table of Contents 1. Revision History ....................................................................................................................... 3 2. Key recommendations .......................................................................................................... 3 3. Purpose and Scope ................................................................................................................. 4 4. Background ............................................................................................................................... 5 5. Methodology .............................................................................................................................. 9 6. Clinical guideline ................................................................................................................... 10 7. References .............................................................................................................................. 16 8. Implementation Strategy ................................................................................................... 19 9. Key Performance Indicators ............................................................................................
    [Show full text]
  • Understanding Peptide Binding in Class a G Protein-Coupled Receptors
    Molecular Pharmacology Fast Forward. Published on July 10, 2019 as DOI: 10.1124/mol.119.115915 This article has not been copyedited and formatted. The final version may differ from this version. MOL# 115915 Understanding peptide binding in Class A G protein-coupled receptors Irina G. Tikhonova, Veronique Gigoux, Daniel Fourmy School of Pharmacy, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 7BL, Northern Ireland, United Kingdom, (I.G.T.) INSERM ERL1226-Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F- 31432 Toulouse, France. (V.G., D.F.) Downloaded from molpharm.aspetjournals.org Keywords: peptides, peptide GPCRs, peptide binding at ASPET Journals on September 30, 2021 1 Molecular Pharmacology Fast Forward. Published on July 10, 2019 as DOI: 10.1124/mol.119.115915 This article has not been copyedited and formatted. The final version may differ from this version. MOL# 115915 Running title page: Peptide Class A GPCRs Corresponding author: Irina G. Tikhonova School of Pharmacy, Medical Biology Centre, 97 Lisburn Road, Queen’s University Belfast, Belfast BT9 7BL, Northern Ireland, United Kingdom Email: [email protected] Tel: +44 (0)28 9097 2202 Downloaded from Number of text pages: 10 Number of figures: 3 molpharm.aspetjournals.org Number of references: 118 Number of tables: 2 Words in Abstract: 163 Words in Introduction: 503 Words in Concluding Remarks: 661 at ASPET Journals on September 30, 2021 ABBREVIATIONS: AT1,
    [Show full text]
  • Responses Induced by Arginine-Vasopressin Injection in the Plasma Concentrations of Adrenocorticotropic Hormone, Cortisol, Growt
    249 Responses induced by arginine-vasopressin injection in the plasma concentrations of adrenocorticotropic hormone, cortisol, growth hormone and metabolites around weaning time in goats K Katoh, M Yoshida, Y Kobayashi, M Onodera, K Kogusa and Y Obara Department of Animal Physiology, Graduate School of Agricultural Science, Tohoku University, Tsutsumidori, Aoba-ku, Sendai 981-8555, Japan (Requests for offprints should be addressed to Y Obara; Email: [email protected]) Abstract In order to assess the biological significance of weaning responses induced by stimulation with AVP were weaker and water deprivation on the control of plasma con- than those induced in 13-week-old goats. Additionally, centrations of adrenocorticotropic hormone (ACTH), cor- there were no responses in any hormone patterns to CRH tisol, growth hormone (GH) and metabolites in response stimulation in 4-week-old goats. In experiment 3, 13- to stimulation with arginine-vasopressin (AVP) and week-old goats were injected with CRH alone followed corticotropin-releasing hormone (CRH), we carried out by injection with AVP for two consecutive days of water three experiments in which male goats before and after deprivation. The animals were subjected to withdrawal of weaning were intravenously injected with AVP or CRH up to 20% of the total blood volume and water deprivation alone, or in combination with each other. In experiment 1, for up to 28 h. However, no significant differences in 17-week-old (post-weaning) goats were intravenously plasma ACTH, cortisol or GH levels were observed injected with AVP or CRH alone at the doses of 0·1, 0·3 between days 1 and 2.
    [Show full text]
  • In Vivo Electrophysiology of Peptidergic Neurons In
    International Journal of Molecular Sciences Article In Vivo Electrophysiology of Peptidergic Neurons in Deep Layers of the Lumbar Spinal Cord after Optogenetic Stimulation of Hypothalamic Paraventricular Oxytocin Neurons in Rats Daisuke Uta 1,*,†, Takumi Oti 2,3,† , Tatsuya Sakamoto 3 and Hirotaka Sakamoto 3,* 1 Department of Applied Pharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan 2 Department of Biological Sciences, Faculty of Science, Kanagawa University, Hiratsuka, Kanagawa 259-1293, Japan; [email protected] 3 Ushimado Marine Institute (UMI), Graduate School of Natural Science and Technology, Okayama University, Ushimado, Setouchi, Okayama 701-4303, Japan; [email protected] * Correspondence: [email protected] (D.U.); [email protected] (H.S.); Tel.: +81-76-434-7513 (D.U.); +81-869-34-5210 (H.S.) † Authors with equal contributions. Abstract: The spinal ejaculation generator (SEG) is located in the central gray (lamina X) of the rat lumbar spinal cord and plays a pivotal role in the ejaculatory reflex. We recently reported that SEG neurons express the oxytocin receptor and are activated by oxytocin projections from the paraventricular nucleus of hypothalamus (PVH). However, it is unknown whether the SEG responds Citation: Uta, D.; Oti, T.; Sakamoto, T.; to oxytocin in vivo. In this study, we analyzed the characteristics of the brain–spinal cord neural Sakamoto, H. In Vivo Electrophysiology circuit that controls male sexual function using a newly developed in vivo electrophysiological of Peptidergic Neurons in Deep Layers technique. Optogenetic stimulation of the PVH of rats expressing channel rhodopsin under the of the Lumbar Spinal Cord after oxytocin receptor promoter increased the spontaneous firing of most lamina X SEG neurons.
    [Show full text]
  • Opioid Modulation of Oxytocin Release
    Review Opioid Modulation of Oxytocin Release Mark S. Morris, BA, Edward F. Domino, MD, and Steven E. Domino, MD Analgesia or anesthesia is frequently used for women in of a labor without sufficient cervical dilatation. This labor. A wide range of opioid analgesics with vastly differ- review discusses the scientific basis for opioid modulation ent pharmacokinetics, potencies, and potential side effects of oxytocin release from the posterior pituitary and the can be considered by physicians and midwives for labor- practical implications of this relationship to explain well- ing patients requesting pain relief other than a labor epi- known clinical observations of the effect of morphine on dural. The past 50 years have seen the use of the classic prodromal labor. mu opioid agonist morphine and other opioids diminish markedly for several reasons, including availability of Keywords: endogenous opioids; morphine; meperidine; epidural anesthetics, side effects, formulary restrictions, mu-kappa-delta opioid receptors; oxytocin; and concern for neonatal respiratory depression. Morphine parturition; vasopressin is now primarily used in obstetrics to provide rest and Journal of Clinical Pharmacology, 2010;50:1112-1117 sedation as appropriate for the stressed prodromal stages © 2010 The Author(s) he major hormone involved with parturition to system in modulating oxytocin release, it is of inter- Tstimulate uterine contractions is oxytocin. est to note the use of exogenous mu opioids such as Russell et al1 have reviewed the extensive literature morphine and meperidine in human parturition. on the complexity of the magnocellular oxytocin Different forms of analgesia/anesthesia are needed system. Endogenous opioids mechanisms inhibit for both the benefit of the woman in labor and her oxytocin release as part of the multiple hormones baby.
    [Show full text]